SCHEMBL17883244

SCHEMBL17883244

O=C(NCCCn1ccnc1)c1cc(-c2ccccc2)n[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.62
CYP3A4 P08684 2/20 0.62
CYP2D6 P10635 2/20 0.62
CYP2C9 P11712 2/20 0.62
CYP2C19 P33261 2/20 0.62
HTT P42858 3/20 0.61
LMNA P02545 2/20 0.61
NPC1 O15118 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
RAB9A P51151 1/20 0.61
HIF1A Q16665 1/20 0.61
HDAC3 O15379 2/20 0.60
HDAC4 P56524 2/20 0.60
HDAC1 Q13547 2/20 0.60
HDAC7 Q8WUI4 2/20 0.60
HDAC2 Q92769 2/20 0.60
HDAC10 Q969S8 2/20 0.60
HDAC11 Q96DB2 2/20 0.60
HDAC8 Q9BY41 2/20 0.60
HDAC6 Q9UBN7 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17874042 0.82 LMNA (0.66) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL13987022 0.80 KDM4E (0.64) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL17874021 0.80 LMNA (0.69) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL30765062 0.79 OPRK1 (0.66) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL27176275 0.79 OPRK1 (0.66) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL27176246 0.79 MEN1 (0.73) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL30087224 0.79 MEN1 (0.73) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1775216 0.79 SMN1; SMN2 (0.82) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL15894134 0.78 KDM4E (0.92) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL30765068 0.78 SMN1; SMN2 (0.70) HTTLMNANPC1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738011-B2 Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis PROTEOSTASIS THERAPEUTICS, INC. (US) 2020-08-11 US disclosed
WO-2016105484-A1 DERIVATIVES OF 5-(HETERO)ARYLPYRAZOL-3-CARBOXYLIC AMIDE OR 1-(HETERO)ARYLTRIAZOL-4-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS PROTEOSTASIS THERAPEUTICS, INC. (US) 2016-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738011-B2 Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis CFTR, SLC33A1, SLC26A4 CYP1A2 2942/4885CYP3A4 1077/4885CYP2D6 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.